HomeCompareJNJ vs RMD

JNJ vs RMD: Dividend Comparison 2026

JNJ yields 2.14% · RMD yields 1.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RMD wins by $1.3K in total portfolio value
10 years
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →
RMD
RMD
● Live price
1.06%
Share price
$220.03
Annual div
$2.33
5Y div CAGR
35.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.7K
Annual income
$3,288.25
Full RMD calculator →

Portfolio growth — JNJ vs RMD

📍 RMD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJNJRMD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JNJ + RMD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JNJ pays
RMD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
RMD
Annual income on $10K today (after 15% tax)
$90.01/yr
After 10yr DRIP, annual income (after tax)
$2,795.01/yr
At 15% tax rate, JNJ beats the other by $1,242.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JNJ + RMD for your $10,000?

JNJ: 50%RMD: 50%
100% RMD50/50100% JNJ
Portfolio after 10yr
$31.1K
Annual income
$4,019.06/yr
Blended yield
12.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
RMD
Analyst Ratings
16
Buy
14
Hold
5
Sell
Consensus: Buy
Price Target
$295.88
+34.5% upside vs current
Range: $265.00 — $345.00
Altman Z
11.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JNJ buys
8
RMD buys
0
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJNJRMD
Forward yield2.14%1.06%
Annual dividend / share$5.20$2.33
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR28%35.9%
Portfolio after 10y$30.5K$31.7K
Annual income after 10y$4,749.88$3,288.25
Total dividends collected$15.6K$10.4K
Payment frequencyquarterlyquarterly
SectorHealthcareHealthcare
Analyst consensusBuyBuy
Analyst price target$228.73$295.88

Year-by-year: JNJ vs RMD ($10,000, DRIP)

YearJNJ PortfolioJNJ Income/yrRMD PortfolioRMD Income/yrGap
1← crossover$10,594$274.49$10,844$143.91$250.00RMD
2$11,294$360.69$11,801$198.21$507.00RMD
3$12,133$476.91$12,901$273.96$768.00RMD
4$13,156$635.42$14,185$380.39$1.0KRMD
5$14,432$854.61$15,709$531.20$1.3KRMD
6$16,056$1,162.76$17,556$747.16$1.5KRMD
7$18,175$1,604.53$19,845$1,060.53$1.7KRMD
8$21,009$2,252.68$22,757$1,522.63$1.7KRMD
9$24,911$3,229.73$26,567$2,217.64$1.7KRMD
10$30,458$4,749.88$31,715$3,288.25$1.3KRMD

JNJ vs RMD: Complete Analysis 2026

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

RMDHealthcare

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Full RMD Calculator →
📬

Get this JNJ vs RMD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JNJ vs ABBVJNJ vs MRKJNJ vs PFEJNJ vs BMYJNJ vs LLYJNJ vs SCHDJNJ vs JEPIJNJ vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.